These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

68 related articles for article (PubMed ID: 2425381)

  • 1. Is conformational analysis a key to solve the structure--activity problem of neuroleptics?
    Misztal S; Mokrosz JL
    Pharmazie; 1986 Apr; 41(4):277-81. PubMed ID: 2425381
    [No Abstract]   [Full Text] [Related]  

  • 2. Stereospecificity and clinical potency of neuroleptics.
    Crow TJ; Deakin JW; Johnstone EC
    Nature; 1977 May; 267(5607):183-4; author reply 184. PubMed ID: 16073446
    [No Abstract]   [Full Text] [Related]  

  • 3. Agents acting on central dopamine receptors.
    Kumar N; Jain PC
    Prog Drug Res; 1977; 21():409-65. PubMed ID: 22892
    [No Abstract]   [Full Text] [Related]  

  • 4. Neuroleptic activity of the 5-aryltetrahydro-gamma-carboline series. Conformational requirements for interaction with central dopamine receptors.
    Harbert CA; Plattner JJ; Welch WM; Weissman A; Koe BK
    Mol Pharmacol; 1980 Jan; 17(1):38-42. PubMed ID: 6104285
    [No Abstract]   [Full Text] [Related]  

  • 5. Conformational properties of butaclamol and isobutaclamol. Regularities in the structures of semirigid neuroleptics.
    Froimowitz M; Matthysse S
    Mol Pharmacol; 1983 Sep; 24(2):243-50. PubMed ID: 6193405
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Computer-aided molecular modelling applied to the dopaminergic system.
    Chrétien JR; Boudon A
    Prog Clin Biol Res; 1989; 291():243-6. PubMed ID: 2567009
    [No Abstract]   [Full Text] [Related]  

  • 7. Antipsychotic drug effects on dopamine and serotonin receptors: in vitro binding and in vivo turnover studies.
    Bacopoulos NG
    J Pharmacol Exp Ther; 1981 Dec; 219(3):708-14. PubMed ID: 6170752
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Brain dopamine receptors.
    Seeman P
    Pharmacol Rev; 1980 Sep; 32(3):229-313. PubMed ID: 6117090
    [No Abstract]   [Full Text] [Related]  

  • 9. No evidence for increased dopamine receptor binding in superresponsive mice after a single dose of neuroleptics.
    Hyttel J
    Adv Biochem Psychopharmacol; 1980; 24():167-73. PubMed ID: 6105773
    [No Abstract]   [Full Text] [Related]  

  • 10. [Role of dopamine receptors in the mechanism of action of neuroleptics].
    Lavretskaia EF; Kats MM; Baldenkov GN
    Zh Nevropatol Psikhiatr Im S S Korsakova; 1985; 85(3):431-5. PubMed ID: 2859724
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evidence that antipsychotic drugs are inverse agonists at D2 dopamine receptors.
    Hall DA; Strange PG
    Br J Pharmacol; 1997 Jun; 121(4):731-6. PubMed ID: 9208141
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dopamine D2 receptor model explains binding affinity of neuroleptics: piquindone and its structure activity relationships.
    Teeter MM; Durand CJ
    Drug Des Discov; 1996 Apr; 13(3-4):49-62. PubMed ID: 8874043
    [No Abstract]   [Full Text] [Related]  

  • 13. Dopamine receptors and schizophrenia: the neuroleptic drug problem.
    Reynolds GP; Riederer P; Jellinger K; Gabriel E
    Neuropharmacology; 1981 Dec; 20(12B):1319-20. PubMed ID: 6119642
    [No Abstract]   [Full Text] [Related]  

  • 14. The role of stereoselectivity of chemosensitizers in the reversal of multidrug resistance of mouse lymphoma cells.
    Szabó D; Molnár J
    Anticancer Res; 1998; 18(4C):3039-44. PubMed ID: 9713506
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Effect of psychotropic drugs on the central dopamine metabolism (example: neuroleptics)].
    Havemann U
    Arzneimittelforschung; 1981; Suppl 27():18-22. PubMed ID: 6118158
    [No Abstract]   [Full Text] [Related]  

  • 16. [Ratio of brain synaptosome Na, K-ATPase to dopamine receptors].
    Glebov RN; Zholob GI; Komissarov IV
    Biull Eksp Biol Med; 1987 Oct; 104(10):430-2. PubMed ID: 2890383
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Design, synthesis and dopamine D4 receptor binding activities of new N-heteroaromatic 5/6-ring Mannich bases.
    Linz S; Müller J; Hübner H; Gmeiner P; Troschütz R
    Bioorg Med Chem; 2009 Jul; 17(13):4448-58. PubMed ID: 19481941
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mapping the dopamine receptor. 2. Features derived from modifications in the rings A/B region of the neuroleptic butaclamol.
    Philipp AH; Humber LG; Voith K
    J Med Chem; 1979 Jul; 22(7):768-73. PubMed ID: 571917
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pyrrolo[1,3]benzothiazepine-based serotonin and dopamine receptor antagonists. Molecular modeling, further structure-activity relationship studies, and identification of novel atypical antipsychotic agents.
    Campiani G; Butini S; Fattorusso C; Catalanotti B; Gemma S; Nacci V; Morelli E; Cagnotto A; Mereghetti I; Mennini T; Carli M; Minetti P; Di Cesare MA; Mastroianni D; Scafetta N; Galletti B; Stasi MA; Castorina M; Pacifici L; Vertechy M; Di Serio S; Ghirardi O; Tinti O; Carminati P
    J Med Chem; 2004 Jan; 47(1):143-57. PubMed ID: 14695828
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Neurotensin, dopamine and mode of action of neuroleptics].
    Tassin JP
    Encephale; 1989; 15(5):465-70. PubMed ID: 2574102
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.